Sanofi Divulges its Strategic Framework to Drive Innovation and Growth

 Sanofi Divulges its Strategic Framework to Drive Innovation and Growth

Sanofi Divulges its Strategic Framework to Drive Innovation and Growth

Shots:

  • Sanofi reveals its focus on its key growth drivers including Dupixent (dupilumab), vaccines and its pipeline consisting of six potentially transformative therapies. The company is expecting Dupixent to generate ~$11B in its annual sales
  • Sanofi also reveals its six investigational therapies which include Fitusiran, BIVV001, Venglustat, SERD (‘859), Nirsevimab, BTKi (‘168) and plan its R&D day in 2020 to provide a detailed review of its R&D portfolio. Sanofi has decided to terminate further research in diabetes & will not pursue plans to launch efpeglenatide
  • Sanofi expects to expand its BOI margin to 30% by 2022 with an aim to exceed it to 32% by 2025. It also plans to separate its OTC business and cut $2.21B in operating costs by 2022. Sanofi will shift its focus to specialty care (immunology, rare diseases, rare blood disorders, neurology and oncology), vaccines and general medicines

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post